---
title: "TLX.US (TLX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TLX.US/news.md"
symbol: "TLX.US"
name: "TLX.US"
parent: "https://longbridge.com/en/quote/TLX.US.md"
datetime: "2026-05-20T00:03:25.320Z"
locales:
  - [en](https://longbridge.com/en/quote/TLX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TLX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TLX.US/news.md)
---

# TLX.US (TLX.US) — Related News

### [IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | TLX Stock News](https://longbridge.com/en/news/286820524.md)
*2026-05-18T13:00:00.000Z*
> Telix Pharmaceuticals has completed patient enrolment for the IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma,

### [Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News](https://longbridge.com/en/news/286547990.md)
*2026-05-15T02:30:35.000Z*
> Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock 

### [A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones](https://longbridge.com/en/news/286344088.md)
*2026-05-14T02:09:48.000Z*
> Telix Pharmaceuticals (ASX:TLX) has gained attention following the FDA's acceptance of its resubmitted New Drug Applicat

### [Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment](https://longbridge.com/en/news/284874178.md)
*2026-05-01T07:40:15.000Z*
> Telix Pharmaceuticals Limited presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx, a radioligand 

### [TLX101-Px (Pixlumi®) MAA Accepted in Europe | TLX Stock News](https://longbridge.com/en/news/284842015.md)
*2026-04-30T13:45:50.000Z*
> TLX101-Px (Pixlumi®) MAA Accepted in Europe | TLX Stock News